SecurityCVO / Cenveo, Inc. (15670S105)
Chairman and CEOBURTON ROBERT G SR
IndustryConverted Paper And Paperboard Products, Except
Institutional Owners7
Institutional Shares3,158,502 - 36.80%
Common Shares Outstanding8,581,964 shares (as of 2017-09-30)
Institutional Value$ 10,160,000 USD
Related 15671BAE1 / Cenveo Corp. 8.875% 02/01/18
CVOVQ / Cenveo Inc
15671BAK7 / Cenveo, Inc. Bond
15671BAL5 / Cenveo, Inc. Bond
15671BAG6 / Cenveo, Inc. Bond
15671BAJ0 / Cenveo, Inc. Bond

Institutional Stock Ownership and Shareholders()

CVO / Cenveo, Inc. Institutional Ownership

Cenveo, Inc. (NASDAQ:CVO) has 7 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 3,158,502 shares. Largest shareholders include Allianz Global Investors U.S. Holdings LLC, Rotation Capital Management, LP, BlackRock Institutional Trust Company, N.A., California Public Employees Retirement System, BlackRock Fund Advisors, BlackRock Advisors LLC, and BlackRock Investment Management, LLC.
Cenveo, Inc. (NASDAQ:CVO) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/cvo"><img src="https://images.fintel.io/us-cvo-so.png" alt="CVO / Cenveo, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-14 13F-HR IHT Wealth Management, LLC 18 0 -100.00 0 0
2018-05-14 13F-HR Pinnacle Holdings, LLC 3,012 0 -100.00 2,711 0 -100.00
2018-05-15 13F-HR BRIDGEWAY CAPITAL MANAGEMENT INC 62,662 0 -100.00 56 0 -100.00
2018-05-15 13F-HR TWO SIGMA SECURITIES, LLC 10,369 0 -100.00 9 0 -100.00
2018-05-01 13F-HR Hanson McClain, Inc. 1,332 0 -100.00 1 0 -100.00
2018-04-17 13F-HR INGALLS & SNYDER LLC 24,885 0 -100.00 22 0 -100.00
2018-04-17 13F-HR BENJAMIN F. EDWARDS & COMPANY, INC. 53,633 0 -100.00 48 0 -100.00
2018-05-10 13F-HR JP Morgan Chase & Co 4,245 0 -100.00 4 0 -100.00
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 56 0 -100.00 0 0
2018-05-17 13F-HR Atlantic Trust Group, LLC 12 0 -100.00 0 0
2018-04-20 13F-HR FIRST MANHATTAN CO 8,836 0 -100.00 7 0 -100.00
2018-05-15 13F-HR UBS Group AG 1,321 0 -100.00 1 0 -100.00
2018-04-18 13F-HR/A FNY Managed Accounts LLC 3,200 0 -100.00 2 0 -100.00
2018-05-14 13F-HR Renaissance Technologies LLC 153,047 0 -100.00 138 0 -100.00
2017-02-10 13F-HR BlackRock Investment Management, LLC 1,293 1,293 0.00 9 9 0.00
2018-05-15 13F-HR RBF Capital, LLC 40,833 0 -100.00 37 0 -100.00
2017-02-14 13F-HR Zelman Capital LLC 487,531 0 -100.00 3,437 0 -100.00
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 40,373 0 -100.00 36 0 -100.00
2018-05-11 13F-HR GSA CAPITAL PARTNERS LLP 16,409 0 -100.00 15 0 -100.00
2017-02-10 13F-HR BlackRock Fund Advisors 17,830 18,534 3.95 126 130 3.17
2018-05-15 13F-HR VANGUARD GROUP INC 94,491 0 -100.00 85 0 -100.00
2017-08-14 13F-HR/A Rotation Capital Management, LP 1,426,782 1,378,744 -3.37 7,162 8,397 17.24
2018-05-14 13F-HR Wallace Capital Management Inc. 92,626 0 -100.00 83 0 -100.00
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 0 230,331 0.00 0 1,610 -0.86
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 10,687 0 -100.00 10 0 -100.00
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 22,062 22,062 0.00 20 1 -95.00
2018-05-14 13F-HR Virtu Financial LLC 35,584 0 -100.00 32 0 -100.00
2017-02-14 SC 13G Allianz Global Investors U.S. Holdings LLC 15,965,301 1,505,696 -90.57
2018-05-09 13F-HR BlackRock Inc. 237,223 0 -100.00 214 0 -100.00
2018-05-14 13F-HR MORGAN STANLEY 6,316 0 -100.00 6 0 -100.00
2018-05-15 13F-HR BARCLAYS PLC 30 0 -100.00 0 0
2018-05-09 13F-HR NORTHERN TRUST CORP 19,714 0 -100.00 17 0 -100.00
2017-02-10 13F-HR BlackRock Advisors LLC 1,842 1,842 0.00 13 13 0.00

Related Articles

HIMX: Himax Technologies Analysis and Research Report

7h - Asif

History and Development Himax Taiwan, its predecessor, was incorporated on June 12, 2001 as a limited liability company under the laws of the ROC. On April 26, 2005, the company established Himax Technologies Limited, an exempted company with limited liability under the Cayman Islands Companies Law, as a holding company to hold the shares of Himax Taiwan in connection with its reorganization and share exchange. On October 14, 2005, Himax Taiwan became its wholly owned subsidiary through a share exchange consummated pursuant to the ROC Business Mergers and Acquisitions Law through which the company acquired all of the issued and outstanding shares of Himax Taiwan, and the company issued ordinary shares to the shareholders of Himax Taiwan. Shareholders of Himax Taiwan received one of its ordinary shares in exchange for one Himax Taiwan common share. The share exchange was unanimously approved by shareholders of Himax Taiwan on June 10, 2005 with no dissenting shareholders and by ...

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

Related News Stories

Assessing Main Street Capital's Results For Q1 2018 (Includes Investment Rating Analysis)

2018-05-09 seekingalpha
This article assesses MAIN’s performance for Q1 2018 and compares results over the trailing twelve months. (23-3)

CUSIP: 15670S105